TRENDING :  Market Movers  |  Top 50   AAPL (-0.23%)    FB (-0.89%)    KO (-0.77%)    AMZN (-0.91%)    UGAZ (4.96%)    VXXB (-3.5%)    MGM (3.07%)    MDB (1.02%)    KRE (2.17%)    AMD (2.38%)    ABMD (1.19%)    AA (0.25%)    IVC (12.08%)    HTGM (2.18%)    GOOS (-2.76%)    GH (4.51%)    GEVO (1.66%)    FUV (-31.27%)    FCEL (12.84%)    DIS (1.75%)    DGAZ (-4.98%)    CRON (2.26%)    CRM (-0.27%)    CGC (3.13%)    CAT (2.7%)

 VKTX - Viking Therapeutics

$9.07 [0.01][0.12%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $16.00
Low $16.00
Average $16.00
Current $9.07

CompanyAnalyst NamePT ActionActionRatingTargetDate
B. Riley FBRAnnouncesInitiates Coverage OnBuy$16.0012/12/18
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



3 Top Biotech Stocks to Buy in February

12:00 AM
Biotech stocks ended 2018 with a thud However the industry has clearly regained its footing early on in 2019 evinced by the iShares Nasdaq Biotechnology Index s 16 surge higher during just the first six weeks of the new year So with the biotech space solidly on the

Should You Buy Viking Therapeutics After Gilead Drug Failure?

InvestorPlace Stock Market News Stock Advice amp Trading Tips Shares of Viking Therapeutics NASDAQ VKTX are making headlines this week after an announcement from Gilead Sciences NASDAQ GILD that one of its drugs did not meet the primary endpoints of its Phase

Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

Shares of Gilead Sciences Inc GILD declined in after market trading on Feb 11 after the company announced the failure of a late stage study on pipeline candidate selonsertib in patients with compensated cirrhosis F4 due to nonalcoholic steatohepatitis NASH Gilead s stock has

Here's Why Viking Therapeutics Rose as Much as 13.9% Today

What happened Shares of Viking Therapeutics NASDAQ VKTX jumped nearly 14 today after Gilead Sciences NASDAQ GILD announced that a closely watched drug candidate failed a phase 3 trial The drug candidate selonsertib was being developed as a potential treatment

5 of the Best Biotech Stocks to Buy Now

InvestorPlace Stock Market News Stock Advice amp Trading Tips It s debatable whether the stock market as a whole had a bear market or just a stiff correction to end 2018 There is however no such question about biotech stocks The sector got clobbered last fall The 160 SPDR S amp